tiprankstipranks
Gilead Sciences (GILD)
NASDAQ:GILD
US Market
GILD
Gilead Sciences
RESEARCH TOOLSreports
Want to see GILD full AI Analyst Report?

Gilead Sciences (GILD) Stock Forecast & Price Target

13,916 Followers
See the Price Targets and Ratings of:

GILD Analyst Ratings

Strong Buy
22Ratings
Strong Buy
19 Buy
3 Hold
0 Sell
Based on 22 analysts giving stock ratings to
Gilead
Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GILD Stock 12 Month Forecast

Average Price Target

$160.37
▲(16.51% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $160.37 with a high forecast of $180.00 and a low forecast of $122.00. The average price target represents a 16.51% change from the last price of $137.64.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"104":"$104","181":"$181","123.25":"$123.3","142.5":"$142.5","161.75":"$161.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":160.3684210526316,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$160.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":122,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$122.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[104,123.25,142.5,161.75,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.244,134.0713846153846,137.89876923076923,141.72615384615384,145.55353846153847,149.38092307692307,153.2083076923077,157.0356923076923,160.86307692307693,164.69046153846153,168.51784615384616,172.34523076923077,176.17261538461537,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.244,132.56126315789473,134.8785263157895,137.19578947368421,139.51305263157894,141.8303157894737,144.14757894736843,146.46484210526316,148.78210526315792,151.09936842105265,153.41663157894737,155.7338947368421,158.05115789473686,{"y":160.3684210526316,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.244,129.60984615384615,128.9756923076923,128.34153846153845,127.70738461538461,127.07323076923078,126.43907692307693,125.80492307692307,125.17076923076922,124.53661538461539,123.90246153846154,123.26830769230769,122.63415384615385,{"y":122,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":105.396,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.893,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.306,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.101,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.08,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.559,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.014,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.155,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.208,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.383,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.79,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.244,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$180.00Average Price Target$160.37Lowest Price Target$122.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Scotiabank Analyst forecast on GILD
Louise Chen
Scotiabank
Scotiabank
$177
Buy
28.60%
Upside
Reiterated
06/18/26
Gilead Sciences (GILD) Gets a Buy from Scotiabank
Citi Analyst forecast on GILD
Geoff Meacham
Citi
Citi
$165
Buy
19.88%
Upside
Reiterated
06/17/26
Gilead Sciences (GILD) Receives a Buy from Citi
Truist Financial Analyst forecast on GILD
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/16/26
Analysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Gilead Sciences (GILD)
Cantor Fitzgerald Analyst forecast on GILD
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$155
Buy
12.61%
Upside
Reiterated
06/16/26
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (NASDAQ: EWTX), Gilead Sciences (NASDAQ: GILD) and Codexis (NASDAQ: CDXS)
Needham Analyst forecast on GILD
Joseph Stringer
Needham
Needham
$170
Buy
23.51%
Upside
Assigned
06/12/26
Gilead Sciences (GILD) Gets a Buy from Needham
Mizuho Securities Analyst forecast on GILD
Salim Syed
Mizuho Securities
Mizuho Securities
$170
Buy
23.51%
Upside
Reiterated
06/12/26
Mizuho Securities Remains a Buy on Gilead Sciences (GILD)
Wells Fargo Analyst forecast on GILD
Mohit Bansal
Wells Fargo
Wells Fargo
$185→$165
Buy
19.88%
Upside
Assigned
06/11/26
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (NASDAQ: ESTA) and Gilead Sciences (NASDAQ: GILD)
Bernstein Analyst forecast on GILD
Courtney Breen
Bernstein
Bernstein
$160
Buy
16.25%
Upside
Reiterated
06/09/26
Gilead Sciences (GILD) Gets a Buy from Bernstein
RBC Capital Analyst forecast on GILD
Brian Abrahams
RBC Capital
RBC Capital
$122
Hold
-11.36%
Downside
Reiterated
06/08/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Hinge Health, Inc. Class A (NYSE: HNGE) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
J.P. Morgan Analyst forecast on GILD
Chris Schott
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/08/26
Buy Rating Reaffirmed on Gilead as HIV Franchise and Oncology Pipeline Offset Trodelvy EVOKE-03 Setback
Morgan Stanley Analyst forecast on GILD
Terence Flynn
Morgan Stanley
Morgan Stanley
$168
Buy
22.06%
Upside
Reiterated
06/04/26
Gilead: Buy Rating Reiterated as Emvistegrast I&I Upside Keeps $168 Price Target Unchanged
Bank of America Securities Analyst forecast on GILD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$162
Buy
17.70%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Gilead Sciences (NASDAQ: GILD) and Celcuity (NASDAQ: CELC)
Jefferies Analyst forecast on GILD
Akash Tewari
Jefferies
Jefferies
$180
Buy
30.78%
Upside
Reiterated
05/22/26
Jefferies Remains a Buy on Gilead Sciences (GILD)
Maxim Group Analyst forecast on GILD
Michael Okunewitch
Maxim Group
Maxim Group
$165
Buy
19.88%
Upside
Upgraded
05/20/26
Gilead upgraded to Buy from Hold at MaximGilead upgraded to Buy from Hold at Maxim
Argus Research Analyst forecast on GILD
Unknown Analyst
Argus Research
Not Ranked
Argus Research
$165
Buy
19.88%
Upside
Reiterated
05/15/26
Argus Research Sticks to Its Buy Rating for Gilead Sciences (GILD)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Scotiabank Analyst forecast on GILD
Louise Chen
Scotiabank
Scotiabank
$177
Buy
28.60%
Upside
Reiterated
06/18/26
Gilead Sciences (GILD) Gets a Buy from Scotiabank
Citi Analyst forecast on GILD
Geoff Meacham
Citi
Citi
$165
Buy
19.88%
Upside
Reiterated
06/17/26
Gilead Sciences (GILD) Receives a Buy from Citi
Truist Financial Analyst forecast on GILD
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/16/26
Analysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Gilead Sciences (GILD)
Cantor Fitzgerald Analyst forecast on GILD
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$155
Buy
12.61%
Upside
Reiterated
06/16/26
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (NASDAQ: EWTX), Gilead Sciences (NASDAQ: GILD) and Codexis (NASDAQ: CDXS)
Needham Analyst forecast on GILD
Joseph Stringer
Needham
Needham
$170
Buy
23.51%
Upside
Assigned
06/12/26
Gilead Sciences (GILD) Gets a Buy from Needham
Mizuho Securities Analyst forecast on GILD
Salim Syed
Mizuho Securities
Mizuho Securities
$170
Buy
23.51%
Upside
Reiterated
06/12/26
Mizuho Securities Remains a Buy on Gilead Sciences (GILD)
Wells Fargo Analyst forecast on GILD
Mohit Bansal
Wells Fargo
Wells Fargo
$185→$165
Buy
19.88%
Upside
Assigned
06/11/26
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (NASDAQ: ESTA) and Gilead Sciences (NASDAQ: GILD)
Bernstein Analyst forecast on GILD
Courtney Breen
Bernstein
Bernstein
$160
Buy
16.25%
Upside
Reiterated
06/09/26
Gilead Sciences (GILD) Gets a Buy from Bernstein
RBC Capital Analyst forecast on GILD
Brian Abrahams
RBC Capital
RBC Capital
$122
Hold
-11.36%
Downside
Reiterated
06/08/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Hinge Health, Inc. Class A (NYSE: HNGE) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
J.P. Morgan Analyst forecast on GILD
Chris Schott
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/08/26
Buy Rating Reaffirmed on Gilead as HIV Franchise and Oncology Pipeline Offset Trodelvy EVOKE-03 Setback
Morgan Stanley Analyst forecast on GILD
Terence Flynn
Morgan Stanley
Morgan Stanley
$168
Buy
22.06%
Upside
Reiterated
06/04/26
Gilead: Buy Rating Reiterated as Emvistegrast I&I Upside Keeps $168 Price Target Unchanged
Bank of America Securities Analyst forecast on GILD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$162
Buy
17.70%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Gilead Sciences (NASDAQ: GILD) and Celcuity (NASDAQ: CELC)
Jefferies Analyst forecast on GILD
Akash Tewari
Jefferies
Jefferies
$180
Buy
30.78%
Upside
Reiterated
05/22/26
Jefferies Remains a Buy on Gilead Sciences (GILD)
Maxim Group Analyst forecast on GILD
Michael Okunewitch
Maxim Group
Maxim Group
$165
Buy
19.88%
Upside
Upgraded
05/20/26
Gilead upgraded to Buy from Hold at MaximGilead upgraded to Buy from Hold at Maxim
Argus Research Analyst forecast on GILD
Unknown Analyst
Argus Research
Not Ranked
Argus Research
$165
Buy
19.88%
Upside
Reiterated
05/15/26
Argus Research Sticks to Its Buy Rating for Gilead Sciences (GILD)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

3 Months
Tyler Van BurenTD Cowen
Success Rate
24/31 ratings generated profit
77%
Average Return
+7.37%
Copying Tyler Van Buren's trades and holding each position for 3 Months would result in 77.42% of your transactions generating a profit, with an average return of +7.37% per trade.
1 Year
Tyler Van BurenTD Cowen
Success Rate
26/31 ratings generated profit
84%
Average Return
+26.92%
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 83.87% of your transactions generating a profit, with an average return of +26.92% per trade.
2 Years
Chris SchottJ.P. Morgan
Success Rate
21/23 ratings generated profit
91%
Average Return
+39.70%
Copying Chris Schott's trades and holding each position for 2 Years would result in 91.30% of your transactions generating a profit, with an average return of +39.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GILD Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
53
50
48
41
55
Hold
10
10
13
12
13
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
63
60
61
53
68
In the current month, GILD has received 55 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. GILD average Analyst price target in the past 3 months is 160.37.
Each month's total comprises the sum of three months' worth of ratings.

GILD Financial Forecast

GILD Earnings Forecast

Next quarter’s earnings estimate for GILD is -$7.32 with a range of -$7.93 to -$6.40. The previous quarter’s EPS was $2.03. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.
Next quarter’s earnings estimate for GILD is -$7.32 with a range of -$7.93 to -$6.40. The previous quarter’s EPS was $2.03. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Sales Forecast

Next quarter’s sales forecast for GILD is $7.41B with a range of $7.22B to $7.65B. The previous quarter’s sales results were $6.98B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.
Next quarter’s sales forecast for GILD is $7.41B with a range of $7.22B to $7.65B. The previous quarter’s sales results were $6.98B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Stock Forecast FAQ

What is GILD’s average 12-month price target, according to analysts?
Based on analyst ratings, Gilead Sciences’s 12-month average price target is 160.37.
    What is GILD’s upside potential, based on the analysts’ average price target?
    Gilead Sciences has 16.51% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GILD a Buy, Sell or Hold?
          Gilead Sciences has a consensus rating of Strong Buy which is based on 19 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Gilead Sciences’s price target?
            The average price target for Gilead Sciences is 160.37. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $180.00 ,the lowest forecast is $122.00. The average price target represents 16.51% Increase from the current price of $137.64.
              What do analysts say about Gilead Sciences?
              Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of GILD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.